Cancer Clinical Trial
Official title:
Relation of Low-risk Lifestyle Behaviours With Cardiovascular Disease, Diabetes, Cancer and All-Cause Mortality: A Series of Systematic Reviews and Meta-analyses of Prospective Cohort Studies
Public health policy is universal in recommending the adoption of low risk low-risk lifestyle behaviors for health promotion and prevention of chronic or non-communicable diseases (NCDs).These behaviors generally include achieving and maintaining a healthy body weight, healthy diet, regular physical activity, smoking cessation, moderate alcohol intake, and adequate sleep. While there is a general consensus that adherence to any one of these low-risk lifestyle behaviors is associated with benefit, it is not clear if adherence to multiple behaviors would result in a larger benefit across different groups of people, conditions, and chronic disease outcomes. The Canadian Cardiovascular Society (CCS), as part of the Dyslipidemia Guidelines Update, commissioned a series of systematic reviews and meta-analyses (a type of knowledge synthesis) using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to quantify the benefit of adherence to multiple low-risk lifestyle behaviors in relation to patient-important chronic disease outcomes (risk of cardiovascular disease, diabetes, cancer, and death) and assesses the quality and strength of the evidence for this benefit.
Rationale:
International health authorities universally recommend adherence to low-risk lifestyle
behaviors for health promotion and prevention of chronic or non-communicable diseases (NCDs).
Systematic reviews and meta-analyses of prospective cohort studies have shown that adherence
to any one low-risk lifestyle behavior, including a healthy body weight, healthy diet,
regular physical activity, smoking cessation, moderate alcohol intake, or adequate sleep, is
associated with less risk of chronic disease. Although individual prospective cohort studies
have shown that adherence to a combination of these low-risk lifestyle behaviors is
associated with an even greater benefit, there are no systematic reviews and meta-analyses
assessing whether it holds across different definitions of low-risk lifestyle behaviors,
levels of exposure, populations, geographical regions, background risks, and chronic disease
outcomes. To inform recommendations for the role of low-risk lifestyle behaviors in chronic
disease prevention, the Canadian Cardiovascular Society (CCS), as part of the Dyslipidemia
Guidelines Update, commissioned a series of systematic reviews and meta-analyses using the
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach of the
association between adherence to a combination of low-risk lifestyle behaviors and (1)
cardiovascular disease (CVD), (2) diabetes, (3) cancer, and (4) all-cause mortality outcomes.
Objectives:
1. To conduct a series of systematic reviews and meta-analyses of the association between
adherene to a combination of low-risk lifestyle behaviors and 4 chronic disease outcomes
(1) cardiovascular disease (cardiovascular disease (CVD) incidence and mortality,
coronary heart disease [CHD] incidence and mortality, and stroke incidence and
mortality), (2) diabetes, (3) cancer (cancer incidence and cancer mortality), and (4)
all-cause mortality.
2. To assess the quality and strength of the evidence using GRADE.
Design:
The planning and conduct of the proposed systematic reviews and meta-analyses will follow the
Cochrane handbook for systematic reviews of interventions. The reporting will follow the
Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.
Data sources:
MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials;
CENTRAL) will be searched using appropriate search terms. These searches will be supplemented
by manual hand searches of the bibliographies of included studies and existing review
articles.
Study selection:
Prospective cohort studies investigating the relation of at-least three low-risk lifestyle
behaviors, one of which must include a healthy diet, with incident cardiovascular disease,
diabetes, cancer or all-cause mortality will be included. Studies will be excluded if
low-risk lifestyle behaviors are combined with biomarkers.
Data extraction:
Two independent reviewers or more will independently extract relevant information about study
design, sample size, subject characteristics, low risk lifestyle behaviors,
duration/person-years of follow-up, adjustments of models. Risk ratios for clinical outcomes
will be extracted or derived from clinical event data across quantiles of exposure.
Risk of bias:
Two independent reviewers or more will assess risk of bias of (ROB) of each of the included
prospective cohort studies using the Newcastle-Ottawa Scale (NOS) by . Up to 9 points can be
awarded based on cohort selection (max 4 points), the comparability of cohort design and
analysis (max 4 points), and adequacy of the outcome measures (max 3 points). Studies that
receive ≥6 points will be considered as higher quality.
Outcomes:
Each of the four proposed systematic reviews and meta-analyses will assess a different
chronic disease outcome: cardiovascular disease (CVD incidence and mortality, CHD incidence
and mortality, and stroke incidence and mortality), (2) diabetes, (3) cancer (cancer and
cancer mortality), and (4) all-cause mortality.
Data synthesis:
Risk estimates of extreme comparisons (all who adhered to low-risk behaviors versus none)
will be pooled using inverse variance random effects models and expressed as risk ratios (RR)
with 95% confidence intervals (CIs). Between-cohort heterogeneity will be assessed by the
Cochran Q (chi-square) statistic and quantified by the I2 statistic. The significance level
will be set at p<0.10 and an I2 ≥ 50% will be considered evidence of substantial
heterogeneity. To explore sources of heterogeneity, the investigators will conduct
sensitivity analyses, in which each study is systematically removed with recalculation of the
summary estimates. If there are >=10 studies, then the investigators will also explore
sources of heterogeneity using a priori subgroup analyses by underlying disease status, sex,
number of lifestyle factors, follow-up (<10 years, ≥10 years), level of adjustment of models,
NOS, ascertainment of outcome, and individual domains of NOS Meta-regression analyses will
assess the significance of categorical and continuous subgroups analyses. Dose-response
analyses will be undertaken using random-effects generalized least squares trend estimation
models (GLST) to assess linear relationships and spline curve modeling (the MKSPLINE
procedure) to assess non-linear relationships. If ≥10 cohort comparisons are available, then
publication bias will be assessed by visual inspection of funnel plots and formally tested
with the Egger and Begg tests at a significance level of p≤ 0.10. If publication bias is
suspected, then the investigators will attempt to adjust for funnel plot asymmetry by
imputing the missing study data using the Duval and Tweedie trim and fill method.
Quality of evidence:
Evidence profiles will be produced the overall strength and quality of the evidence will be
assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
system. This system grades the evidence as "high quality", "moderate quality", "low quality",
or "very low quality". The included prospective cohort studies will start at "low quality" by
default and then be downgraded or upgraded based on pre-specified criteria. Criteria to
downgrade will include study limitations (weight of studies show risk of bias by NOS),
inconsistency (substantial unexplained inter-study heterogeneity, I2>50% and P<0.10),
indirectness (presence of factors relating to the population, exposures, and outcomes that
limit generalizability), imprecision (95% CI are wide or cross a minimally important
difference of 10% [RR 0.9- 1.1]), and publication bias (significant evidence of small-study
effects). Criteria to upgrade will include a large magnitude effect (RR>2 or RR<0.5 in the
absence of plausible confounders), a dose-response gradient, and attenuation by plausible
confounding effects.
Knowledge translation plan:
The results will be disseminated through interactive presentations at local, national, and
international scientific meetings and publication in high impact factor journals. Target
audiences will include the public health and scientific communities with interest in
nutrition, physical activity, lifestyle modification, diabetes, cancer and cardiovascular
disease. Feedback will be incorporated and used to improve the public health message and key
areas for future research will be defined.
Significance:
The proposed project will aid in knowledge translation related to the effects of low-risk
lifestyle behaviours on cardiovascular disease, diabetes, cancer, and all-cause mortality,
strengthening the evidence-base for recommendations and improving health outcomes through
informing consumers and public health policy makers, stimulating industry innovation, and
guiding future research.
Role of the funding sources:
The funding source will have no role in the research question, design, analysis, results and
interpretation of the results of this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|